ResearchMoz added Latest Research Report titled " Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015: World Market Research, Analysis, Shares, Size, Trends, Growth, Survey, Forecast " to it's Large Report database.

Albany, NY -- (SBWire) -- 12/10/2015 --Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For more details get a smple of this report at: http://www.researchmoz.us/enquiry.php?type=S&repid=487840

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst

chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

Chapter 4 provides a review of the leading licensing deals since 2011. Deals are listed by headline value, signed by bigpharma, most active big pharma, signed by big biotech, most active big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2011, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2011 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Report description: http://www.researchmoz.us/global-licensing-terms-agreements-in-pharma-biotech-diagnostics-20112015-report.html

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 provides the reader with the following key benefits:

In-depth understanding of licensing partnering deal trends since 2011
Insight into the terms included in a licensing agreement, together with real world clause examples
Identify leading licensing deals by value since 2011
Identify the most active licensing dealmakers since 2011
Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
Comprehensive access to over 3,500 licensing deals entered into by the world's biopharma companies, together with contract documents if available
Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us